We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
190 hedge funds and large institutions have $543M invested in ANI Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 57 increasing their positions, 54 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
110% more call options, than puts
Call options by funds: $6.86M | Put options by funds: $3.26M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more capital invested
Capital invested by funds: $319M → $543M (+$224M)
12% more funds holding
Funds holding: 170 → 190 (+20)
5.25% more ownership
Funds ownership: 59.76% → 65% (+5.2%)
6% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 54
Holders
190
Holders Change
+20
Holders Change %
+11.76%
% of All Funds
4.11%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
37
Increased
57
Reduced
54
Closed
17
Calls
$6.86M
Puts
$3.26M
Net Calls
+$3.6M
Net Calls Change
+$3.16M
Top Buyers
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$3.39M |
| 2 |
Citigroup
New York
|
-$2.21M |
| 3 |
Bank of New York Mellon
New York
|
-$1.75M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$1.66M |
| 5 |
WAM
Wellesley Asset Management
Portsmouth,
New Hampshire
|
-$1.28M |
